R-MVST Cells for Treatment of Viral Infections
Phase 1
36
about 4.7 years
18+
1 site in NY
What this study is about
Researchers are testing the safety and feasibility of giving R-MVST cells to people with viral infections. The goal is to see if these cells can help fight off viruses like Epstein-Barr Virus, cytomegalovirus, adenovirus, or BK virus. The trial will also look at how well the treatment works, any side effects that might occur, and whether it improves overall survival.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Rapidly generated virus specific T (R-MVST) cells
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Incidence of toxicity that leads to safety endpoint
Secondary: Overall survival rate, Percentage of subjects with good response in viral load or end-organ disease improvement
Infectious